TORONTO, Jan. 10, 2022 /PRNewswire/ – Tripsitter Clinic Ltd. (CSE: KETA) (FSE: UY0) (“TripSitter Clinic” or the “Company“), a virtual clinic and tele-health company, is pleased to announce that the Company’s shares have been accepted for listing on the Frankfurt Stock Exchange (“FSE”) and commenced trading on January 5, 2022 under the symbol “UY0”.
The Company’s common shares are now cross listed on the Canadian Securities Exchange and the FSE. The FSE is one of the world’s leading international stock exchanges by revenue, profitability, and market capitalization and is the largest of Germany’s stock exchanges.
“This listing on the Frankfurt Stock Exchange is an exciting milestone for the team. There is significant demand from investors in Europe for tele-health platforms like ours, and we are pleased that it will now be easier for those investors to participate in our growth, particularly as we continue to expand our global footprint,” said Dr. John Huber, CEO of TripSitter Clinic.
The Company entered into a service contract dated December 7, 2021 (the “Service Contract”) with MMG Market Medium GmbH & Co. KG (“MMG”), pursuant to which MMG will provide marketing and consulting services, including certain investor relations services, for the purpose of creating market awareness of the Company. The terms of the Service Contract with MMG include an initial payment of EUR 200,000 for a four-to-six-week period commencing in January 2022. The Service Contract may be extended for additional terms at the discretion of the Company.
Changes to the board of directors
On December 13th, 2021, Andrew Parks resigned from the Company’s board of directors. On January 14th, 2022, Roger Daher resigned from the board of directors. The Company is delighted to announce the appointment of Richard Dolan to the board of directors.
Richard is a twenty-five year veteran, world renowned thought leader, author and coach inside the domain of human betterment and performance. Richard is the co-author of ‘Performance: Codifying Human Excellence Through Sport Psychology‘ published by Routledge and has served as a performance advisor to professional athletes across the MLB, F1, NHL and the NBA; where he earned three NBA Championship rings (two with the Miami Heat, one with the Los Angeles Lakers). “My life’s work intention is to empower people to reclaim and restore their relationship to peak performance in mind, and TripSitter is on the cutting edge of doing just that’ says Dolan. “Developing modalities and creating new means to have all people gain access to their signature suite of services within the ever-growing world of psychedelic-orientated experiences and treatments is sound work TripSitter is performing and I am pleased to join them in this quest” concludes Dolan.
Learn more about TripSitter Clinic here: https://www.tripsitter.clinic/.
About TripSitter Clinic Ltd.
TripSitter, through its wholly-owned subsidiary, TripSitter Clinic Corp., operates a consultative virtual clinic and tele-health platform that connects prospective patients to a licensed physician in the United States who can evaluate for a prescribed treatment program of low-dose, oral ketamine medication. The licensed physicians within the platform consult and coordinate with the primary care physician (“PCP“) of the prospective patient, if they are approved for treatment. TripSitter is not a PCP and requires each prospective patient to provide their information to their PCP during the initial intake process. The PCP is assigned to the patient by the patient’s own physician. TripSitter is proud to be at the forefront of the emerging wave of consultative medicine that prioritizes patient access and quality of care while leveraging an internationally recognized platform of remote diagnostic and patient monitoring. TripSitter’s platform, TripSitter.Clinic, is a mobile-first, responsive webapp that acts as a virtual clinic, connecting patients with licensed medical practitioners. TripSitter.Clinic operates as a SaaS platform, functioning as the intermediary between patient and practitioner.
ON BEHALF OF THE BOARD of DIRECTORS
“Dr. John Huber“
Dr. John Huber
No securities regulatory authority has either approved or disapproved of the contents of this news release.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities of TripSitter in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act“), or any state securities laws. Accordingly, the securities may not be offered or sold within the U.S. or to U.S. persons (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws, or pursuant to exemptions from the registration requirements of the U.S. Securities Act and applicable state securities laws.
Disclaimer for Forward-Looking Information
This news release includes certain forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities legislation. The use of any of the words “expect”, “anticipate“, “continue“, “estimate“, “objective“, “may”, “will”, “project“, “should”, “believe”, “plans”, “intends” and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Forward-looking information in this news release includes statements concerning the Company’s general business plans, the tele-health industry and the Company’s market position within it, and statements concerning the listing of the Company’s common shares on the CSE. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors that could materially affect such forward-looking information are described in the risk factors in the Company’s final long-form prospectus dated November 22, 2021, and the schedules attached thereto, that are available on the Company’s profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable laws.pcp ketamine psychedelic investors shares stock exchange trading cse empower regulation laws